Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Ixekizumab confers efficacy for up to 4 years in moderate-to-severe psoriasis

01 Aug 2018

It appears that the efficacy of ixekizumab treatment in patients with moderate-to-severe psoriasis lasts for up to 4 years, according to a phase II study.

The investigators performed analysis by last observation carried forward involving patients who received ixekizumab 120 mg and then 80 mg subcutaneously once every 4 weeks.

Ninety-three percent of the patients who completed the randomized placebo-controlled trial entered the open-label extension (OLE). There was a 75-percent decrease in the Psoriasis Area Severity Index score in 82 percent of patients at week 208 of the OLE.

Sixty-four percent of patients had a static Physician Global Assessment score of 0 or 1, and 45 percent had a score of 0 at week 208. Compared with baseline, a decrease was observed in the patients’ Dermatology Life Quality Index and Itch visual analogue scale scores. There were also improvements in other efficacy and health outcome measures.

Serious adverse events (AE) were reported in 16.7 percent of patients, and 87 percent had one or more treatment-emergent AE. Serious infections occurred in three patients, while one patient reported two major cardiovascular events.

This study was limited by the lack of a placebo or active comparator, and it was also unblinded.

A previous phase III trial (UNCOVER-3) has found that ixekizumab is well tolerated and yields persistent efficacy through 108 weeks. [J Am Acad Dermatol 2017;77:855-862]

“Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.